IMRIS, Deerfield Imaging, the global leader in intraoperative imaging, announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new InVision 1.5 Surgical Theatre, a ceiling-mounted intraoperative MRI system specifically designed for imaging during surgical procedures in a multi-room operating suite. This newest technology is a 1.5T system that provides high quality imaging for neurosurgical applications.

“We’re excited to receive regulatory clearance for commercialization of our InVision 1.5 Surgical Theatre,” said IMRIS CEO Marc Buntaine. “IMRIS continues to innovate and provide intraoperative imaging solutions that support the clinical needs of hospitals and doctors that treat neurological disorders. This new InVision system further expands and complements the IMRIS product portfolio by offering the latest innovations in 1.5T MRI.”

IMRIS custom designs innovative intraoperative MRI systems specifically for imaging during neurosurgical procedures. An IMRIS InVision Surgical Theatre helps deliver timely information to clinicians, providing real-time visualization to assist in decision-making and enhance precision in treatment.